AlphaCrest Capital Management LLC lifted its position in shares of Humana Inc. (NYSE:HUM – Get Rating) by 60.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,010 shares of the insurance provider’s stock after acquiring an additional 1,507 shares during the period. AlphaCrest Capital Management LLC’s holdings in Humana were worth $1,877,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in the company. Townsend & Associates Inc bought a new position in Humana in the second quarter worth about $206,000. Krane Funds Advisors LLC boosted its position in Humana by 4.2% during the 1st quarter. Krane Funds Advisors LLC now owns 889 shares of the insurance provider’s stock valued at $387,000 after purchasing an additional 36 shares during the period. Private Advisor Group LLC grew its stake in Humana by 32.3% during the 2nd quarter. Private Advisor Group LLC now owns 15,520 shares of the insurance provider’s stock worth $7,265,000 after buying an additional 3,788 shares during the last quarter. CCLA Investment Management Ltd boosted its holdings in shares of Humana by 1.4% during the first quarter. CCLA Investment Management Ltd now owns 218,232 shares of the insurance provider’s stock valued at $95,075,000 after acquiring an additional 3,034 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in Humana by 2.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 57,029 shares of the insurance provider’s stock worth $26,694,000 after purchasing an additional 1,282 shares during the last quarter. 93.50% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, insider Joseph C. Ventura sold 1,226 shares of the stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $506.78, for a total value of $621,312.28. Following the completion of the sale, the insider now owns 3,930 shares in the company, valued at $1,991,645.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Humana news, CAO William Kevin Fleming sold 11,157 shares of the company’s stock in a transaction that occurred on Thursday, November 3rd. The shares were sold at an average price of $565.61, for a total value of $6,310,510.77. Following the transaction, the chief accounting officer now owns 2,542 shares in the company, valued at approximately $1,437,780.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Joseph C. Ventura sold 1,226 shares of Humana stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $506.78, for a total transaction of $621,312.28. Following the sale, the insider now directly owns 3,930 shares of the company’s stock, valued at approximately $1,991,645.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,161 shares of company stock worth $16,994,804. Corporate insiders own 0.39% of the company’s stock.
Humana Stock Performance
Humana Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 27th. Investors of record on Friday, December 30th will be paid a $0.7875 dividend. This represents a $3.15 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date is Thursday, December 29th. Humana’s dividend payout ratio is 14.29%.
Analysts Set New Price Targets
Several research firms have commented on HUM. StockNews.com raised shares of Humana from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 4th. Credit Suisse Group raised their price objective on shares of Humana from $548.00 to $635.00 and gave the company an “outperform” rating in a research note on Thursday, November 3rd. Mizuho upped their target price on Humana from $529.00 to $615.00 and gave the stock a “buy” rating in a research report on Thursday, November 10th. Deutsche Bank Aktiengesellschaft upgraded Humana from a “hold” rating to a “buy” rating and lifted their price target for the company from $514.00 to $576.00 in a research report on Wednesday, October 26th. Finally, Cowen upped their price objective on Humana from $547.00 to $647.00 in a report on Monday, November 7th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $579.00.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.